Most importantly, in the context of an irrelevant TC2 tumor, mice vaccinated with B16-CSDE1* reacted against both the TC2-expressed CSDE1* and, albeit to a lesser extent, against the CSDE1 epitope, thereby confirming that the APOBEC3B-mutated CSDE1* acts as a heteroclitic peptide (p < 0.001 one-way ANOVA). The gene discussed is APOBEC3B; the disease is neoplasm.